abstract |
The present invention provides a dosing schedule for intratumoral delivery of immunostimulatory cytokines in combination with systemic delivery of checkpoint inhibitors. Specifically, the present invention provides the use of electroporation for the intratumoral delivery of plasmids encoding immunostimulatory cytokines, such as IL-12, as well as systemic delivery of PD-1 antagonists. |